| 02/02 | Allogene Therapeutics Presents Data on Dagger, a Next Generation AlloCAR T Platform Tec.. | AQ |
| 01/02 | Allogene Therapeutics Presents Data on Dagger™, a Next Generation AlloCAR T&trade.. | GL |
| 01/02 | Allogene Therapeutics Presents Data on Dagger™, a Next Generation AlloCAR T&trade.. | GL |
| 25/01 | Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1.. | AQ |
| 25/01 | Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting.. | GL |
| 25/01 | Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting.. | GL |
| 24/01 | Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1.. | GL |
| 17/01 | Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences | GL |
| 04/01 | Allogene Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference | GL |
| 04/01 | Allogene Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference | AQ |
| 03/01 | Allogene Therapeutics, Inc. : Change in Directors or Principal Officers (form 8-K) | AQ |
| 03/01 | Allogene Appoints Zachary J. Roberts, M.D., Ph.D. as Executive Vice President of Resear.. | GL |
| 03/01 | Allogene Appoints Zachary J. Roberts, M.D., Ph.D. as Executive Vice President of Resear.. | AQ |
| 2022 | Relapsing Refractory Multiple Myeloma Pipeline as Novel and Extensive 60+ Therapies Lik.. | AQ |
| 2022 | Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across.. | AQ |
| 2022 | Allogene Therapeutics, Inc. : Other Events (form 8-K) | AQ |
| 2022 | Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across.. | GL |
| 2022 | Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across.. | GL |
| 2022 | Allogene Therapeutics Unveils Novel Approach to Generate Engineered AlloCAR T Cells to .. | AQ |
| 2022 | Allogene Therapeutics Unveils Novel Approach to Generate Engineered AlloCAR T™ Ce.. | GL |
| 2022 | Allogene Therapeutics Unveils Novel Approach to Generate Engineered AlloCAR T™ Ce.. | AQ |
| 2022 | Allogene Therapeutics To Host Research & Development Showcase and Participate in Five U.. | GL |
| 2022 | Allogene Therapeutics To Host Research & Development Showcase and Participate in Five U.. | AQ |
| 2022 | Allogene Therapeutics Announces Poster Presentation of Its Phase 1 UNIVERSAL Trial in M.. | GL |
| 2022 | Allogene Therapeutics Announces Poster Presentation of Its Phase 1 UNIVERSAL Trial in M.. | AQ |
| 2022 | ALLOGENE THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Conditio.. | AQ |
| 2022 | Allogene Therapeutics, Inc. : Results of Operations and Financial Condition (form 8-K) | AQ |
| 2022 | Allogene Therapeutics : Q3 Earnings Snapshot | AQ |
| 2022 | Allogene Therapeutics Reports Third Quarter 2022 Financial Results and Announces Invest.. | GL |
| 2022 | Allogene Overland Biopharm Completes Buildout of cGMP Manufacturing Facility in Shangha.. | AQ |
| 2022 | Allogene Overland Biopharm Completes Buildout of cGMP Manufacturing Facility in Shangha.. | GL |
| 2022 | Allogene Overland Biopharm Completes Buildout of cGMP Manufacturing Facility in Shangha.. | AQ |
| 2022 | Allogene Therapeutics to Report Third Quarter 2022 Financial Results on November 2, 202.. | GL |
| 2022 | Allogene Therapeutics to Report Third Quarter 2022 Financial Results on November 2, 202.. | GL |
| 2022 | Allogene Therapeutics Launches CAR T Together, a First-of-its-Kind Initiative with Lead.. | AQ |
| 2022 | Allogene Therapeutics Launches CAR T Together™, a First-of-its-Kind Initiative wi.. | GL |
| 2022 | Allogene Therapeutics Launches CAR T Together™, a First-of-its-Kind Initiative wi.. | AQ |
| 2022 | Allogene Therapeutics Initiates Industry's First Allogeneic CAR T Phase 2 Trial | AQ |
| 2022 | Allogene Therapeutics, Inc. : Other Events (form 8-K) | AQ |
| 2022 | Allogene Therapeutics Initiates Industry's First Allogeneic CAR T Phase 2 Trial | GL |
| 2022 | Allogene Stocks Fall as Servier Abandons Anti-CD19 Partnership | AQ |
| 2022 | Allogene Therapeutics Announces Participation in the Jefferies Cell and Genetic Medicin.. | GL |
| 2022 | Allogene Therapeutics : Current Report - Form 8-K | PU |
| 2022 | Allogene Therapeutics, Inc. : Other Events (form 8-K) | AQ |
| 2022 | Allogene Therapeutics : August 2022 Corporate Presentation | PU |
| 2022 | Allogene Therapeutics : Reports Second Quarter 2022 Financial Results - Form 8-K | PU |
| 2022 | Allogene Therapeutics : Q2 Earnings Snapshot | AQ |
| 2022 | ALLOGENE THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Conditio.. | AQ |
| 2022 | Allogene Therapeutics, Inc. : Results of Operations and Financial Condition (form 8-K) | AQ |
| 2022 | Allogene Therapeutics Reports Second Quarter 2022 Financial Results | GL |
| 2022 | Allogene Therapeutics Reports Second Quarter 2022 Financial Results | AQ |
| 2022 | Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences | GL |
| 2022 | Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences | GL |
| 2022 | Allogene Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022 | GL |
| 2022 | Allogene Therapeutics, Inc. : Change in Directors or Principal Officers (form 8-K) | AQ |
| 2022 | Allogene Therapeutics Appoints Scientific Pioneer Stephen Mayo to its Board of Director.. | GL |
| 2022 | Allogene Therapeutics, Inc. : Submission of Matters to a Vote of Security Holders, Financi.. | AQ |
| 2022 | Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy .. | GL |
| 2022 | Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy .. | AQ |
| 2022 | Allogene Therapeutics : ALLO May 2022 Corporate Presentation | PU |
| 2022 | Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Imp.. | GL |
| 2022 | Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Imp.. | AQ |
| 2022 | Allogene Therapeutics Named 2022 Bay Area 'Best Place to Work' by San Francisco Busines.. | AQ |
| 2022 | Allogene Therapeutics Named 2022 Bay Area “Best Place to Work” by San Franc.. | GL |
| 2022 | ALLOGENE THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Conditio.. | AQ |
| 2022 | Allogene Therapeutics : Q1 Earnings Snapshot | AQ |
| 2022 | Allogene Therapeutics, Inc. : Results of Operations and Financial Condition (form 8-K) | AQ |
| 2022 | Allogene Therapeutics Reports First Quarter 2022 Financial Results | GL |
| 2022 | Allogene Therapeutics Reports First Quarter 2022 Financial Results | AQ |
| 2022 | Allogene Therapeutics Receives FDA Orphan-Drug Designation for ALLO-605, its First Turb.. | AQ |
| 2022 | Allogene Therapeutics Appoints Susan Lundeen as Chief People Officer | GL |
| 2022 | Allogene Therapeutics to Report First Quarter 2022 Financial Results on May 4, 2022 | AQ |
| 2022 | Allogene Therapeutics Receives FDA Orphan-Drug Designation for ALLO-605, its First Turb.. | AQ |
| 2022 | Allogene Therapeutics : ALLO April 2022 Corporate Presentation | PU |
| 2022 | Allogene Therapeutics Publishes Preclinical Data on ALLO-316, an AlloCAR T Candidate Ta.. | AQ |
Google
Twitter
Facebook
Apple
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Rapport
